세계의 위암 시장 2021년-2031년 : 질병 유형별 (선암종, 림프종, 위장관 간질성 종양, 카르시노이드 종양, 기타), 치료 유형별 (면역 요법, 표적 치료제, 화학 요법, 방사선 치료 및 수술), 약제 종류별 (PD-1 및 PD-L1 억제제, HER2 길항제, VEGFR2 길항제, 기타), 투여 경로별 (경구, 주사제), 유통 채널별 (병원 약국, 전문 약국 및 소매 약국, 기타)

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
3.6. Average Selling Price
3.7. Brand Share Analysis
3.8. Key Regulation Analysis
3.9. Market Share Analysis
3.10. Patent Landscape
3.11. Regulatory Guidelines
3.12. Value Chain Analysis
CHAPTER 4: GASTRIC CANCER MARKET, BY DISEASE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Adenocarcinoma
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Lymphoma
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Gastrointestinal Stromal Tumor
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Carcinoid Tumor
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Others
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: GASTRIC CANCER MARKET, BY TREATMENT TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Immunotherapy
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Targeted Therapy
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Chemotherapy
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Radiation Therapy and Surgery
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK
6.1. Overview
6.1.1. Market size and forecast
6.2. PD-1/PD-L1 Inhibitors
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. HER2 Antagonists
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. VEGFR2 Antagonists
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Others
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
CHAPTER 7: GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION
7.1. Overview
7.1.1. Market size and forecast
7.2. Oral
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Injectable
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
CHAPTER 8: GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL
8.1. Overview
8.1.1. Market size and forecast
8.2. Hospital Pharmacies
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by region
8.2.3. Market share analysis by country
8.3. Specialty and Retail Pharmacies
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by region
8.3.3. Market share analysis by country
8.4. Others
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Market size and forecast, by region
8.4.3. Market share analysis by country
CHAPTER 9: GASTRIC CANCER MARKET, BY REGION
9.1. Overview
9.1.1. Market size and forecast By Region
9.2. North America
9.2.1. Key trends and opportunities
9.2.2. Market size and forecast, by Disease Type
9.2.3. Market size and forecast, by Treatment Type
9.2.4. Market size and forecast, by Drug Class Outlook
9.2.5. Market size and forecast, by Route of Administration
9.2.6. Market size and forecast, by Distribution Channel
9.2.7. Market size and forecast, by country
9.2.7.1. U.S.
9.2.7.1.1. Key market trends, growth factors and opportunities
9.2.7.1.2. Market size and forecast, by Disease Type
9.2.7.1.3. Market size and forecast, by Treatment Type
9.2.7.1.4. Market size and forecast, by Drug Class Outlook
9.2.7.1.5. Market size and forecast, by Route of Administration
9.2.7.1.6. Market size and forecast, by Distribution Channel
9.2.7.2. Canada
9.2.7.2.1. Key market trends, growth factors and opportunities
9.2.7.2.2. Market size and forecast, by Disease Type
9.2.7.2.3. Market size and forecast, by Treatment Type
9.2.7.2.4. Market size and forecast, by Drug Class Outlook
9.2.7.2.5. Market size and forecast, by Route of Administration
9.2.7.2.6. Market size and forecast, by Distribution Channel
9.2.7.3. Mexico
9.2.7.3.1. Key market trends, growth factors and opportunities
9.2.7.3.2. Market size and forecast, by Disease Type
9.2.7.3.3. Market size and forecast, by Treatment Type
9.2.7.3.4. Market size and forecast, by Drug Class Outlook
9.2.7.3.5. Market size and forecast, by Route of Administration
9.2.7.3.6. Market size and forecast, by Distribution Channel
9.3. Europe
9.3.1. Key trends and opportunities
9.3.2. Market size and forecast, by Disease Type
9.3.3. Market size and forecast, by Treatment Type
9.3.4. Market size and forecast, by Drug Class Outlook
9.3.5. Market size and forecast, by Route of Administration
9.3.6. Market size and forecast, by Distribution Channel
9.3.7. Market size and forecast, by country
9.3.7.1. Germany
9.3.7.1.1. Key market trends, growth factors and opportunities
9.3.7.1.2. Market size and forecast, by Disease Type
9.3.7.1.3. Market size and forecast, by Treatment Type
9.3.7.1.4. Market size and forecast, by Drug Class Outlook
9.3.7.1.5. Market size and forecast, by Route of Administration
9.3.7.1.6. Market size and forecast, by Distribution Channel
9.3.7.2. UK
9.3.7.2.1. Key market trends, growth factors and opportunities
9.3.7.2.2. Market size and forecast, by Disease Type
9.3.7.2.3. Market size and forecast, by Treatment Type
9.3.7.2.4. Market size and forecast, by Drug Class Outlook
9.3.7.2.5. Market size and forecast, by Route of Administration
9.3.7.2.6. Market size and forecast, by Distribution Channel
9.3.7.3. France
9.3.7.3.1. Key market trends, growth factors and opportunities
9.3.7.3.2. Market size and forecast, by Disease Type
9.3.7.3.3. Market size and forecast, by Treatment Type
9.3.7.3.4. Market size and forecast, by Drug Class Outlook
9.3.7.3.5. Market size and forecast, by Route of Administration
9.3.7.3.6. Market size and forecast, by Distribution Channel
9.3.7.4. Spain
9.3.7.4.1. Key market trends, growth factors and opportunities
9.3.7.4.2. Market size and forecast, by Disease Type
9.3.7.4.3. Market size and forecast, by Treatment Type
9.3.7.4.4. Market size and forecast, by Drug Class Outlook
9.3.7.4.5. Market size and forecast, by Route of Administration
9.3.7.4.6. Market size and forecast, by Distribution Channel
9.3.7.5. Italy
9.3.7.5.1. Key market trends, growth factors and opportunities
9.3.7.5.2. Market size and forecast, by Disease Type
9.3.7.5.3. Market size and forecast, by Treatment Type
9.3.7.5.4. Market size and forecast, by Drug Class Outlook
9.3.7.5.5. Market size and forecast, by Route of Administration
9.3.7.5.6. Market size and forecast, by Distribution Channel
9.3.7.6. Rest of Europe
9.3.7.6.1. Key market trends, growth factors and opportunities
9.3.7.6.2. Market size and forecast, by Disease Type
9.3.7.6.3. Market size and forecast, by Treatment Type
9.3.7.6.4. Market size and forecast, by Drug Class Outlook
9.3.7.6.5. Market size and forecast, by Route of Administration
9.3.7.6.6. Market size and forecast, by Distribution Channel
9.4. Asia-Pacific
9.4.1. Key trends and opportunities
9.4.2. Market size and forecast, by Disease Type
9.4.3. Market size and forecast, by Treatment Type
9.4.4. Market size and forecast, by Drug Class Outlook
9.4.5. Market size and forecast, by Route of Administration
9.4.6. Market size and forecast, by Distribution Channel
9.4.7. Market size and forecast, by country
9.4.7.1. China
9.4.7.1.1. Key market trends, growth factors and opportunities
9.4.7.1.2. Market size and forecast, by Disease Type
9.4.7.1.3. Market size and forecast, by Treatment Type
9.4.7.1.4. Market size and forecast, by Drug Class Outlook
9.4.7.1.5. Market size and forecast, by Route of Administration
9.4.7.1.6. Market size and forecast, by Distribution Channel
9.4.7.2. Japan
9.4.7.2.1. Key market trends, growth factors and opportunities
9.4.7.2.2. Market size and forecast, by Disease Type
9.4.7.2.3. Market size and forecast, by Treatment Type
9.4.7.2.4. Market size and forecast, by Drug Class Outlook
9.4.7.2.5. Market size and forecast, by Route of Administration
9.4.7.2.6. Market size and forecast, by Distribution Channel
9.4.7.3. India
9.4.7.3.1. Key market trends, growth factors and opportunities
9.4.7.3.2. Market size and forecast, by Disease Type
9.4.7.3.3. Market size and forecast, by Treatment Type
9.4.7.3.4. Market size and forecast, by Drug Class Outlook
9.4.7.3.5. Market size and forecast, by Route of Administration
9.4.7.3.6. Market size and forecast, by Distribution Channel
9.4.7.4. South Korea
9.4.7.4.1. Key market trends, growth factors and opportunities
9.4.7.4.2. Market size and forecast, by Disease Type
9.4.7.4.3. Market size and forecast, by Treatment Type
9.4.7.4.4. Market size and forecast, by Drug Class Outlook
9.4.7.4.5. Market size and forecast, by Route of Administration
9.4.7.4.6. Market size and forecast, by Distribution Channel
9.4.7.5. Australia
9.4.7.5.1. Key market trends, growth factors and opportunities
9.4.7.5.2. Market size and forecast, by Disease Type
9.4.7.5.3. Market size and forecast, by Treatment Type
9.4.7.5.4. Market size and forecast, by Drug Class Outlook
9.4.7.5.5. Market size and forecast, by Route of Administration
9.4.7.5.6. Market size and forecast, by Distribution Channel
9.4.7.6. Rest of Asia-Pacific
9.4.7.6.1. Key market trends, growth factors and opportunities
9.4.7.6.2. Market size and forecast, by Disease Type
9.4.7.6.3. Market size and forecast, by Treatment Type
9.4.7.6.4. Market size and forecast, by Drug Class Outlook
9.4.7.6.5. Market size and forecast, by Route of Administration
9.4.7.6.6. Market size and forecast, by Distribution Channel
9.5. LAMEA
9.5.1. Key trends and opportunities
9.5.2. Market size and forecast, by Disease Type
9.5.3. Market size and forecast, by Treatment Type
9.5.4. Market size and forecast, by Drug Class Outlook
9.5.5. Market size and forecast, by Route of Administration
9.5.6. Market size and forecast, by Distribution Channel
9.5.7. Market size and forecast, by country
9.5.7.1. Brazil
9.5.7.1.1. Key market trends, growth factors and opportunities
9.5.7.1.2. Market size and forecast, by Disease Type
9.5.7.1.3. Market size and forecast, by Treatment Type
9.5.7.1.4. Market size and forecast, by Drug Class Outlook
9.5.7.1.5. Market size and forecast, by Route of Administration
9.5.7.1.6. Market size and forecast, by Distribution Channel
9.5.7.2. United Arab Emirates
9.5.7.2.1. Key market trends, growth factors and opportunities
9.5.7.2.2. Market size and forecast, by Disease Type
9.5.7.2.3. Market size and forecast, by Treatment Type
9.5.7.2.4. Market size and forecast, by Drug Class Outlook
9.5.7.2.5. Market size and forecast, by Route of Administration
9.5.7.2.6. Market size and forecast, by Distribution Channel
9.5.7.3. Saudi Arabia
9.5.7.3.1. Key market trends, growth factors and opportunities
9.5.7.3.2. Market size and forecast, by Disease Type
9.5.7.3.3. Market size and forecast, by Treatment Type
9.5.7.3.4. Market size and forecast, by Drug Class Outlook
9.5.7.3.5. Market size and forecast, by Route of Administration
9.5.7.3.6. Market size and forecast, by Distribution Channel
9.5.7.4. South Africa
9.5.7.4.1. Key market trends, growth factors and opportunities
9.5.7.4.2. Market size and forecast, by Disease Type
9.5.7.4.3. Market size and forecast, by Treatment Type
9.5.7.4.4. Market size and forecast, by Drug Class Outlook
9.5.7.4.5. Market size and forecast, by Route of Administration
9.5.7.4.6. Market size and forecast, by Distribution Channel
9.5.7.5. Rest of LAMEA
9.5.7.5.1. Key market trends, growth factors and opportunities
9.5.7.5.2. Market size and forecast, by Disease Type
9.5.7.5.3. Market size and forecast, by Treatment Type
9.5.7.5.4. Market size and forecast, by Drug Class Outlook
9.5.7.5.5. Market size and forecast, by Route of Administration
9.5.7.5.6. Market size and forecast, by Distribution Channel
CHAPTER 10: COMPETITIVE LANDSCAPE
10.1. Introduction
10.2. Top winning strategies
10.3. Product Mapping of Top 10 Player
10.4. Competitive Dashboard
10.5. Competitive Heatmap
10.6. Top player positioning, 2021
CHAPTER 11: COMPANY PROFILES
11.1. Novartis AG
11.1.1. Company overview
11.1.2. Key Executives
11.1.3. Company snapshot
11.2. Pfizer, Inc.
11.2.1. Company overview
11.2.2. Key Executives
11.2.3. Company snapshot
11.3. Mylan N.V.
11.3.1. Company overview
11.3.2. Key Executives
11.3.3. Company snapshot
11.4. F. Hoffmann La Roche Ltd.
11.4.1. Company overview
11.4.2. Key Executives
11.4.3. Company snapshot
11.5. Eli Lilly And Company
11.5.1. Company overview
11.5.2. Key Executives
11.5.3. Company snapshot
11.6. Merck & Co., Inc.
11.6.1. Company overview
11.6.2. Key Executives
11.6.3. Company snapshot
11.7. Teva Pharmaceutical Industries Ltd.
11.7.1. Company overview
11.7.2. Key Executives
11.7.3. Company snapshot
11.8. Celltrion Healthcare Co., Ltd.
11.8.1. Company overview
11.8.2. Key Executives
11.8.3. Company snapshot
11.9. samsung bioepis
11.9.1. Company overview
11.9.2. Key Executives
11.9.3. Company snapshot
11.10. Bristol Myers Squibb Company
11.10.1. Company overview
11.10.2. Key Executives
11.10.3. Company snapshot